PHARMACOKINETICS OF BID VERSUS QID DOSING OF SULFADIAZINE IN HIV-INFECTED PATIENT
PHARMACOKINETICS OF BID VERSUS QID DOSING OF SULFADIAZINE IN HIV-INFECTED PATIENT
批准号:
6289452
负责人:
STEPHEN PISCITELLI
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
本研究是一项开放、随机、交叉的研究,目的是比较每日两次或每日四次磺胺嘧啶的药代动力学。10名CD4计数低于500的人类免疫缺陷病毒感染患者将被招募。患者必须没有并发机会性感染,并且必须愿意遵守研究方案。本研究旨在比较两种剂量磺胺嘧啶的药代动力学参数和血清浓度:1000mg QID和2000mg BID。此外,本研究将评估这些给药方案的安全性和耐受性。目前,该研究已获得IRB批准,并将在未来1至2个月内开始招募。
英文摘要
This study is an open-label, randomized, cross-over study to compare the pharmacokinetics of sulfadiazine given on twice daily or four times daily schedule. Ten human immunodeficiency virus-infected patients with CD4 counts below 500 will be enrolled. Patients must not hae concurrent opportunistic infections and must be willing to comply with the study regimen. The study is designed to compare pharmacokinetic parameters and serum conentrations of sulfadiazine at two doses: 1000mg QID and 2000 mg BID. Additionally, this study wll assess the safety and tolerance of these dosage regimens. Currently, the study has received IRB approval and will begin enrolling within the next 1 to 2 months.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pharmacokinetics of BID versus QID Dosing of Sulfadiazine in HIV-infected Patien
-
批准号:6431831
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEPHEN PISCITELLI
-
依托单位:
THE EFFECT OF RITONAVIR ON THE PHARMACOKINETICS OF MEPERIDINE IN HIV-NEGATIVE SUB
-
批准号:6103662
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEPHEN PISCITELLI
-
依托单位:
Pharmacokinetics of BID versus QID Dosing of Sulfadiazine in HIV-infected Patient
-
批准号:6103663
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEPHEN PISCITELLI
-
依托单位:
EFFECT OF GARLIC ON PHARMACOKINETICS OF SAQUINAVIR
-
批准号:6414325
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:STEPHEN PISCITELLI
-
依托单位:
海外基金